Custom Compounding Center, Little Rock, AR
Is Custom Compounding Center registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Custom Compounding Center hold a Arkansas pharmacy license?
State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5275 for Custom Compounding Center, LITTLE ROCK, AR, status Expired, as of Nov 15, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000403 for CUSTOM COMPOUNDING CENTER (dba PHARMACY COMPOUNDING VENTURES, LLC), LITTLE ROCK, AR, status INACTIVE, as of Nov 15, 2026.
Has Custom Compounding Center had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Oct 28, 2020), 1 state referral letter (Oct 28, 2020) and 1 FMD-145 letter (Oct 28, 2020) for Custom Compounding Center. State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Custom Compounding Center
- Location
- Little Rock, AR
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Oct 28, 2020
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 7 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Custom Compounding Center, a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Oct 28, 2020 | FMD-145 letter | FMD-145 Letter Issued 10/28/2020 | FDA copy (archived) |
| Oct 28, 2020 | Warning letter close-out | Warning Letter Close Out Issued 10/28/2020 | Not linked by FDA |
| Oct 28, 2020 | State referral letter | Referral Letter to the Arkansas State Board of Pharmacy Issued 10/28/2020 | FDA copy (archived) |
| Jun 4, 2019 | Form 483 | 483 Issued 06/04/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Custom Compounding Center, Little Rock, AR (FEI number 3002401385), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jun 4, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3002401385 | 1092014 |
| Apr 9, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3002401385 | 921931 |
Form 483s FDA has published for this site
- Jun 4, 2019: Form 483 to Custom Compounding Center, published Jul 12, 2019. fda.gov
- Jul 23, 2015: Form 483 to Custom Compounding Center, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 7 numbered observations in all, across 2 inspections ending Apr 9, 2015 to Jun 4, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 29, 2019 to Jun 4, 2019: 1 observation
- Firm on the cover
- Custom Compounding Center, 11700 Kanis Rd, Little Rock, AR 72211-3729
- Establishment type on the cover
- Producer of Drug Products
- FDA district office on the cover
- DISTRICT ADDR ESS AND PHONE NUMBER 4040 Nort h Central Expressway, Suite 300 Dallas, TX 75204
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You produced hazardous drugs without providing adequate cleaning of work surfaces to prevent cross-contamination.
Specifically,
Your firm failed to utilize an oxidizing agent to clean immediately following the handling of testosterone, estrogen, and morphine containing drug products in your <Redacted B4> hoods, <Redacted B4> serial number <Redacted B4> and <Redacted B4> serial number <Redacted B4> your firm only utilizes <Redacted B4> to clean between compounding drug products, per your standard operating procedure, "Room Cleaning Procedures and Spill Handling" , SOP #3.007.
Inspection Mar 30, 2015 to Apr 9, 2015: 6 observations
- Firm on the cover
- Custom Compounding Center, 11700 Kanis R oad, Little Rock, AR 72211-3745
- FEI number
- 3002401385
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 4040 North Central Expressway, Suite 300 Dallas, TX 75204
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
Specifically,
A. On 03/31/2015, your firm’s Owner/Pharmacist-in-Charge stated your firm fa iled to ade quately certify methods and processed used for the p roductio n equipme nt, REDACTED (B)(4) (ID # REDACTED (B)(4)) and the REDACTED (B)(4) (ID # REDACTED (B)(4)) used in the depyrogenation and sterilization of production glassw are an d REDACTED (B)(4)., B. On 03/30/2015, your firm's Owner/Pharmacist-in-Charge stated your firm failed to validate any of t he processes used to render produced drugs sterile. For example, during the production of Avastin (NDC # 500242-00 60) your firm failed to validate the repackaging operati on which is used to render a non-sterile component sterile for the Supplier Lot # REDACTED (B)(4) /your firm's Lot
# 03302015+4264@8., C. On 03/30/2015, during our walkthrough of your facility's Cleanroom REDACTED (B)(4) Chemotherapy room (ISO 7 Classified), we observed your Pharmacy Technician exhibiting poor aseptic techniques in that:
1. ...
Observation 2
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically.
A. Your firm failed to adequately validate the following sterile and non-sterile drug production areas currently
DATE ISSUEO
PAOI! I OF J rAGES
FORM FDA iBl (09108)
PRF.VIOlJS EDil'ION OPSOLelF.
B. On 03/30/2015, we observed three Magnehelic gauges on the exterior wall of the Powder Room (ISO 7 classified) leading to cleanroom areas failed to physically measure generated and maintained differential pressures levels in both static and dynamic states.
Observation 3
The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.
Specifically,
A. During a review of your firm's 2014-2 015 Environmental Monitoring REDACTED (B)(4) Analysis, smoke pattern studies, for sterile and non-sterile drug production ISO 5 Classified REDACTED (B)(4) (Sterile - REDACTED (B)(4) Model # REDACTED (B)(4) S/N REDACTED (B)(4) and Non Sterile REDACTED (B)(4) , S/N REDACTED (B)(4) , your firm failed to perform these studies in the dynamic state. On 4/1/2015, your firm's Owner/Pharmacist-in-charge stated all smoke studies were completed in the REDACTED (B)(4).
your
stated all smoke srudies were completed i11 the
B. On 03/30/2015, we observed your firm's weigh scales in the Powder Room (ISO 7 classified) are environmentally exposed without adequate containment to prevent powder particulate cross-contamination of drug products during admixing.
C. Your firm failed to define a written control system for the plastic slated doors leading into all ISO classified areas to prevent drug product contamination.
Observation 4
Protective apparel is not worn as necessary to protect drug products from contamination.
Specifically,
A. Your firm failed to require adequate protective apparel to protect drug products from contamination. For example your firm's Pharmacy Technician was observed having facial and neck areas exposed during the repackaging of Avastin (NDC # 500242-0060), Supplier Lot REDACTED (B)(4)/Firm’s Lot 03302015+4264@8 1.25mg/0.05ml syringes.
B. Your firm fails to require use of sterile hair nets and face masks during the production of sterile drug products.
C. Your firm fails to require the continuous use of sterile gowning during the production of sterile drug products. For example on 3/30/2015, a sterile gown used by your firm's Pharmacy Technician was observed hanging on the corner of a stainless steel shelving located in the ISO 7 Classified Ante-room. Your firm's procedure, Room Cleaning Procedures-Compounding Labs-Sterile & Non Sterile (SOP# 5.005, Implemented date 9/19/14), reports shelving cleaning occurs only REDACTED (B)(4). Your firm reuses a single gown an entire drug production day.
FOilM FilA 433 (09/08) PRe\~OU S EDJTION ODSOI.ETE INS I'ECTIONAL OBSERVATIONS
PAGU 2 OF l PAGES
Observation 5
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, on 03/30/2015, your firm’s Owner/Pharmacist-in-Charge stated your firm failed to have a written stability program f or all sterile and non-sterile drug products.
Observation 6
Representative samples are not taken of each shipment of each lot of components for testing or examination.
Specifically, on 03/30/2015, your firm's Owner/Pharmacist-in-charge stated your firm failed to have a written procedure for receiving, inspecting, and accepting lots of non-sterile components utilized in the production of sterile finished drug products.
State board of pharmacy records
State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 5275 | OSP | Custom Compounding Center | LITTLE ROCK, AR | Expired |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0000403 | NONRESIDENT PHARMACY | CUSTOM COMPOUNDING CENTER (dba PHARMACY COMPOUNDING VENTURES, LLC) | LITTLE ROCK, AR | INACTIVE |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
- Connecticut Department of Consumer Protection license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.